|
Form 4 Filings | Insider Buys | Significant Buys |
Penny Stocks Insider Buying |
Insider Sales |
| Insider Buy Sell Ratios | Stock Options |
Insider Trading Stock Screener |
Insider Trading Graph View |
Insider Watch |
Sec Filings Insider Trading - CRISPR Therapeutics AG (CRSP)
|
|
"Insiders might sell their shares for any number of reasons, but they buy them for only one:
they think the price will rise" - Peter Lynch ==>> What is insider trading>> |
Historical filings delayed by 6 months. New user?
Sign Up for real time data.
Existing user?
Sign In
Common stock purchase or sale:
| Transaction Date |
Reported Date |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2017-08-31 Sale |
2017-09-05 6:33 pm |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
18,470 | $20.76 | $383,393 | 1,151,860 (Direct) |
View |
| 2017-08-28 Sale |
2017-08-30 6:36 pm |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
75,795 | $20.25 | $1,534,869 | 1,232,697 (Direct) |
View |
| 2017-08-28 Sale |
2017-08-30 6:12 pm |
CRISPR Therapeutics AG | CRSP | Kulkarni Samarth Chief Business Officer |
27,154 | $20.08 | $545,162 | 110,893 (Direct) |
View |
| 2017-08-28 Sale |
2017-08-30 4:18 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
88,011 | $19.79 | $1,741,738 | 1,951,359 (Indirect) |
View |
| 2017-08-24 Sale |
2017-08-28 4:33 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
22,781 | $19.42 | $442,403 | 2,054,283 (Indirect) |
View |
| 2017-08-22 Sale |
2017-08-24 4:02 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
17,989 | $18.53 | $333,336 | 2,069,186 (Indirect) |
View |
| 2017-08-18 Sale |
2017-08-22 4:02 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
3,150 | $18.52 | $58,345 | 2,081,390 (Indirect) |
View |
| 2017-08-16 Sale |
2017-08-18 4:16 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
34,141 | $19.06 | $650,693 | 2,096,883 (Indirect) |
View |
| 2017-08-14 Sale |
2017-08-16 4:14 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
55,569 | $19.59 | $1,088,561 | 2,143,017 (Indirect) |
View |
| 2017-08-07 Sale |
2017-08-09 4:12 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
35,473 | $18.63 | $660,888 | 2,210,722 (Indirect) |
View |
| 2017-08-04 Sale |
2017-08-08 5:52 pm |
CRISPR Therapeutics AG | CRSP | Dylan-Hyde Tyler Chief Legal Officer |
15,000 | $18.57 | $278,479 | 167,727 (Direct) |
View |
| 2017-08-03 Sale |
2017-08-07 4:18 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
50,477 | $17.81 | $899,216 | 2,229,413 (Indirect) |
View |
| 2017-07-31 Sale |
2017-08-02 4:21 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
5,512 | $17.51 | $96,491 | 2,277,086 (Indirect) |
View |
| 2017-07-27 Sale |
2017-07-31 4:07 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
41,312 | $17.63 | $728,134 | 2,282,734 (Indirect) |
View |
| 2017-07-25 Sale |
2017-07-27 4:51 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
32,930 | $17.6 | $579,545 | 2,347,390 (Indirect) |
View |
| 2017-07-13 Sale |
2017-07-17 4:11 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
69,859 | $16.84 | $1,176,710 | 2,392,806 (Indirect) |
View |
| 2017-07-11 Sale |
2017-07-13 4:00 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
31,992 | $16.56 | $529,938 | 2,426,435 (Indirect) |
View |
| 2017-07-05 Sale |
2017-07-07 4:24 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
4,254 | $16.26 | $69,170 | 2,440,555 (Indirect) |
View |
| 2017-06-28 Sale |
2017-06-30 4:50 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
43,202 | $16.9 | $730,125 | 2,456,419 (Indirect) |
View |
| 2017-06-26 Sale |
2017-06-28 4:05 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
81,435 | $17.08 | $1,390,611 | 2,521,445 (Indirect) |
View |
| 2017-06-22 Sale |
2017-06-26 4:39 pm |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
32,368 | $16.23 | $525,302 | 2,600,287 (Indirect) |
View |
| 2017-06-22 Sale |
2017-06-23 4:20 pm |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
10,825 | $15.37 | $166,388 | 1,225,830 (Direct) |
View |
| 2017-06-19 Sale |
2017-06-21 5:42 pm |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
30,222 | $15.01 | $453,511 | 1,266,583 (Direct) |
View |
| 2017-06-08 Sale |
2017-06-12 5:02 pm |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
5,303 | $15.02 | $79,628 | 1,219,208 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported Date |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2017-11-13 Option Award |
2017-11-14 5:19 pm |
N/A 2027-11-21 |
CRISPR Therapeutics AG | CRSP | TOMSICEK MICHAEL JOHN Chief Financial Officer |
180,000 | $17.75 | 180,000 (Direct) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
1,368,013 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
8,110 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
814,599 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
23,899 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
61,993 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
26,491 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
292,529 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
292,529 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
17,283 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
17,283 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
1,240 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:35 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Versant Venture Capital IV L.P. Versant Side Fund IV L.P. Versant Venture Capital V L.P. Versant Affiliates Fund V L.P. Versant Ophthalmic Affiliates I L.P. Versant Venture Capital V (Canada) LP Versant Ventures IV LLC Versant Ventures V LLC Versant Ventures V (Canada) L.P. 10% Owner |
1,240 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
1,368,013 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
8,110 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
814,599 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
23,899 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
61,993 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
26,491 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
292,529 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
292,529 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
17,283 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
17,283 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
1,240 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
1,240 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
9,918 | $0 | 2,736,032 (Direct) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
1,368,013 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
8,110 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
814,599 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
23,899 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
61,993 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
26,491 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
292,529 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
292,529 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
17,283 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
17,283 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
1,240 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
1,240 | $0 | 2,736,032 (Indirect) |
View |
| 2017-09-05 Other |
2017-09-07 9:32 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
55,447 | $0 | 2,736,032 (Direct) |
View |
| 2017-08-31 Exercise |
2017-09-05 6:33 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
3,853 | $1.81 | 1,151,860 (Direct) |
View |
| 2017-08-31 Exercise |
2017-09-05 6:33 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
3,853 | $1.81 | 1,151,860 (Direct) |
View |
| 2017-08-28 Exercise |
2017-08-30 6:36 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
17,692 | $1.81 | 1,232,697 (Direct) |
View |
| 2017-08-28 Exercise |
2017-08-30 6:36 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
5,722 | $1.81 | 1,232,697 (Direct) |
View |
| 2017-08-28 Exercise |
2017-08-30 6:36 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
17,692 | $1.81 | 1,232,697 (Direct) |
View |
| 2017-08-28 Exercise |
2017-08-30 6:36 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
5,722 | $1.81 | 1,232,697 (Direct) |
View |
| 2017-08-01 Option Award |
2017-08-02 4:30 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Ho Tony W See Remarks |
75,000 | $0 | 260,000 (Direct) |
View |
| 2017-08-01 Option Award |
2017-08-02 4:30 pm |
N/A 2027-08-01 |
CRISPR Therapeutics AG | CRSP | Ho Tony W See Remarks |
260,000 | $16.9 | 260,000 (Direct) |
View |
| 2017-06-22 Exercise |
2017-06-23 4:20 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
10,825 | $1.81 | 1,225,830 (Direct) |
View |
| 2017-06-22 Exercise |
2017-06-23 4:20 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
10,825 | $1.81 | 1,225,830 (Direct) |
View |
| 2017-06-19 Exercise |
2017-06-21 5:42 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
15,392 | $1.81 | 1,266,583 (Direct) |
View |
| 2017-06-19 Exercise |
2017-06-21 5:42 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
3,252 | $1.81 | 1,266,583 (Direct) |
View |
| 2017-06-19 Exercise |
2017-06-21 5:42 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
11,578 | $1.81 | 1,266,583 (Direct) |
View |
| 2017-06-19 Exercise |
2017-06-21 5:42 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
15,392 | $1.81 | 1,266,583 (Direct) |
View |
| 2017-06-19 Exercise |
2017-06-21 5:42 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
3,252 | $1.81 | 1,266,583 (Direct) |
View |
| 2017-06-19 Exercise |
2017-06-21 5:42 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
11,578 | $1.81 | 1,266,583 (Direct) |
View |
| 2017-06-15 Option Award |
2017-06-19 4:05 pm |
N/A 2027-06-15 |
CRISPR Therapeutics AG | CRSP | Dylan-Hyde Tyler Chief Legal Officer |
65,000 | $14.43 | 65,000 (Direct) |
View |
| 2017-06-15 Option Award |
2017-06-19 4:05 pm |
N/A 2027-06-15 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
270,000 | $14.43 | 270,000 (Direct) |
View |
| 2017-06-15 Option Award |
2017-06-19 4:05 pm |
N/A 2027-06-15 |
CRISPR Therapeutics AG | CRSP | Subramanian Kala See Remarks |
85,000 | $14.43 | 85,000 (Direct) |
View |
| 2017-06-08 Exercise |
2017-06-12 5:02 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
4,203 | $1.81 | 1,219,208 (Direct) |
View |
| 2017-06-08 Exercise |
2017-06-12 5:02 pm |
N/A N/A |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
1,100 | $1.81 | 1,219,208 (Direct) |
View |
| 2017-06-08 Exercise |
2017-06-12 5:02 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
4,203 | $1.81 | 1,219,208 (Direct) |
View |
| 2017-06-08 Exercise |
2017-06-12 5:02 pm |
N/A 2025-09-10 |
CRISPR Therapeutics AG | CRSP | Novak Rodger Chief Executive Officer Director |
1,100 | $1.81 | 1,219,208 (Direct) |
View |
| 2017-05-31 Option Award |
2017-06-02 4:37 pm |
N/A 2027-05-31 |
CRISPR Therapeutics AG | CRSP | George Simeon Director |
15,000 | $13.62 | 15,000 (Direct) |
View |
| 2017-05-31 Option Award |
2017-06-02 4:33 pm |
N/A 2027-05-31 |
CRISPR Therapeutics AG | CRSP | Behbahani Ali Director |
15,000 | $13.62 | 15,000 (Direct) |
View |
| 2017-05-31 Option Award |
2017-06-02 4:31 pm |
N/A 2027-05-31 |
CRISPR Therapeutics AG | CRSP | EMSTER KURT VON Director |
15,000 | $13.62 | 15,000 (Direct) |
View |
| 2017-05-31 Option Award |
2017-06-02 4:30 pm |
N/A 2027-05-31 |
CRISPR Therapeutics AG | CRSP | CAGNONI PABLO J Director |
15,000 | $13.62 | 15,000 (Direct) |
View |
| 2017-05-31 Option Award |
2017-06-02 4:30 pm |
N/A 2027-05-31 |
CRISPR Therapeutics AG | CRSP | Woiwode Thomas Director |
30,000 | $13.62 | 30,000 (Indirect) |
View |
| 2017-05-31 Option Award |
2017-06-02 4:30 pm |
N/A 2027-05-31 |
CRISPR Therapeutics AG | CRSP | Bolzon Bradley J PhD Director |
30,000 | $13.62 | 30,000 (Indirect) |
View |
| 2017-05-31 Option Award |
2017-06-02 4:30 pm |
N/A 2027-05-31 |
CRISPR Therapeutics AG | CRSP | KASINGER JAMES R. General Counsel and Secretary |
123,000 | $13.62 | 123,000 (Direct) |
View |
|
© 2005-2018 SecForm4.Com All rights reserved. Archives: 2018 2017 2016 2015 2014 2013 ... Mon, 21 May 2018 06:14:38 -0500 |
SEC is the U.S. Securities and Exchange Commission. EDGAR is a trademark of the SEC. SecForm4.Com is not affiliated with or approved by the U.S. Securities and Exchange Commission (SEC). Terms of Use | Privacy Statement | |